Clinical Trial Update: A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in ALS [Phase 2]

View source ↗

Summary

A multicenter Phase 2 study assessing safety and pharmacokinetics of arimoclomol in ALS has completed, reporting results from dose-ranging evaluation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• Arimoclomol (arimoclomol)

Snippet

Sponsor: CytRx | Conditions: Amyotrophic Lateral Sclerosis (ALS) | Phase 2 | Status: COMPLETED